(Q38042711)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971033%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Impact of restricting access to high-cost medications for hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971033%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971033%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Daniel H Palmer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971033%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971033%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Pharmacoeconomics & Outcomes Research

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971033%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971033%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971033%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

465-473

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971033%20AND%20SRC:MED&resulttype=core&format=json

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

13 February 2020

cites work

1 reference

21 January 2018

Hepatocellular carcinoma

1 reference

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy

21 January 2018

1 reference

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

21 January 2018

1 reference

Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study

21 January 2018

1 reference

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

21 January 2018

1 reference

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

21 January 2018

1 reference

Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).

21 January 2018

1 reference

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

21 January 2018

1 reference

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness

21 January 2018

1 reference

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [

21 January 2018

1 reference

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

21 January 2018

1 reference

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERP.12.33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971033%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference